A key focus for Ananda is developing the evidence required to prove the efficacy of its cannabinoid medicines, and we are motivated by the calls of UK regulators for evidence to unlock NHS funding.

MRX Medical is providing one of its cannabidiol formulations, MRX1, into two Phase II clinical trials that have received a combined £1.55 million in non-dilutive funding.

One of the clinical trials will use one of our formulations to target the treatment of Chemotherapy Induced Peripheral Neuropathy (CIPN), which approximately 160,000 people in the UK are diagnosed with each year. The other trial will use the same formulation to target the treatment of the pain associated with endometriosis, which is suffered by 1.5 million women in the UK.

In addition to these funded trials, Ananda continues to develop a pipeline of opportunities to further build evidence through clinical trials.